Lee YT, Wang JJ, Luu M, et al. The mortality and overall survival trends of primary liver cancer in the United States. J Natl Cancer Inst. 2021;113(11):1531–41. https://doi.org/10.1093/jnci/djab079.

Article  PubMed  PubMed Central  Google Scholar 

Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898–907. https://doi.org/10.1038/s12276-020-00527-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96(9): e5904. https://doi.org/10.1097/MD.0000000000005904.

Article  PubMed  Google Scholar 

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl. 1):S35-50. https://doi.org/10.1053/j.gastro.2004.09.014.

Article  PubMed  Google Scholar 

Cancer facts & figures 2023. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html. Accessed 16 Apr 2024.

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001.

Article  CAS  PubMed  Google Scholar 

Abboud Y, Ismail M, Khan H, et al. Hepatocellular carcinoma incidence and mortality in the USA by sex, age, and race: a nationwide analysis of two decades. J Clin Transl Hepatol. 2024;12(2):172–81. https://doi.org/10.14218/JCTH.2023.00356.

Article  PubMed  PubMed Central  Google Scholar 

Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: from bench to bedside. World J Gastrointest Oncol. 2021;13(4):197–215. https://doi.org/10.4251/wjgo.v13.i4.197.

Article  PubMed  PubMed Central  Google Scholar 

McMahon B, Cohen C, Brown RS Jr, et al. Opportunities to address gaps in early detection and improve outcomes of liver cancer. JNCI Cancer Spectr. 2023;7(3):pkad034. https://doi.org/10.1093/jncics/pkad034.

Article  PubMed  PubMed Central  Google Scholar 

Huang L, Kang D, Zhao C, Liu X. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Sci Rep. 2024;14(1):4327. https://doi.org/10.1038/s41598-024-54945-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang B, Shi X, Cui K, et al. Real-world practice of conversion surgery for unresectable hepatocellular carcinoma: a single center data of 26 consecutive patients. BMC Cancer. 2023;23(1):465. https://doi.org/10.1186/s12885-023-10955-7.

Article  PubMed  PubMed Central  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830–50. https://doi.org/10.1200/JCO.23.02745.

Article  CAS  PubMed  Google Scholar 

Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162(3):920–34. https://doi.org/10.1053/j.gastro.2021.12.276.

Article  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8): EVIDoa2100070. https://doi.org/10.1056/EVIDoa2100070.

Article  PubMed  Google Scholar 

Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448–57. https://doi.org/10.1016/j.annonc.2024.02.005.

Article  CAS  PubMed  Google Scholar 

Center for Drug Evaluation and Research. FDA approves tremelimumab in combination with durvalumab. US Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma. Accessed 16 Apr 2024.

Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis. Oncologist. 2020;25(3):e512–9. https://doi.org/10.1634/theoncologist.2019-0501.

Article  CAS  PubMed  Google Scholar 

Li D, Gruber SB, Iyer S, Gupta S, Tejani M. Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. World J Gastrointest Oncol. 2023;15(10):1796–806. https://doi.org/10.4251/wjgo.v15.i10.1796.

Article  PubMed  PubMed Central  Google Scholar 

Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https://doi.org/10.1001/jamanetworkopen.2021.0037.

Article  PubMed  PubMed Central  Google Scholar 

Meyers BM, Vogel A, Marotta P, et al. The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Can J Gastroenterol Hepatol. 2021;2021:8811018. https://doi.org/10.1155/2021/8811018.

Article  PubMed  PubMed Central  Google Scholar 

Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020;40(12):1167–76. https://doi.org/10.1007/s40261-020-00983-7.

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. https://doi.org/10.1016/j.jval.2021.11.1351.

Article  PubMed  Google Scholar 

Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https://doi.org/10.1186/s12874-021-01308-8.

Article  PubMed  PubMed Central  Google Scholar 

Drevon D, Fursa SR, Malcolm AL. Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data. Behav Modif. 2017;41(2):323–39. https://doi.org/10.1177/0145445516673998.

Article  PubMed  Google Scholar 

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.

Article  PubMed  PubMed Central  Google Scholar 

Nice DSU technical support document 14. https://www.ncbi.nlm.nih.gov/books/n/nicetechsup14/pdf. Accessed 18 Apr 2024.

Extrapolating clinical evidence within economic evaluations. https://www.cadth.ca/sites/default/files/attachments/2023-05/MH0011-ExtrapolatingClinicalEvidenceWithinEconomicEvaluations_0.pdf. Accessed 18 Apr 2024.

Micromedex Red Book: patient education. Merative. https://www.merative.com/micromedex-training-center/red-book. Accessed 18 Apr 2024.

Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2018;110(5):479–85. https://doi.org/10.1093/jnci/djx226.

Article  PubMed  Google Scholar 

Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25(11):1739–46. https://doi.org/10.1111/j.1440-1746.2010.06404.x.

Article  PubMed  Google Scholar 

Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237–48. https://doi.org/10.1002/hep.28961.

Article  PubMed  Google Scholar 

May P, Normand C, Cassel JB, et al. Economics of palliative care for hospitalized adults with serious illness: a meta-analysis. JAMA Intern Med. 2018;178(6):820–9. https://doi.org/10.1001/jamainternmed.2018.0750.

Article  PubMed  PubMed